Soleo Health Chosen as Specialized Pharmacy Partner for RYPLAZIM® in Treating Plasminogen Deficiency Type 1 (PLGD-1)
Soleo Health, a prominent provider of specialized pharmacy services for rare and ultra-rare diseases, has been designated as a limited distribution specialty pharmacy partner for dispensing RYPLAZIM® (plasminogen, human-tvmh), developed…
GlycoMimetics Reveals Findings from Crucial Phase 3 Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), a biotechnology company specializing in advanced therapies for cancer and inflammatory conditions, has released the top-line results from its Phase 3 global pivotal trial of uproleselan…
Oregon Therapeutics & Lantern Pharma Team Up to Advance Novel Cancer Drug XCE853 with AI
Lantern Pharma Inc. (NASDAQ: LTRN), a prominent player in artificial intelligence (AI)-driven oncology drug discovery and development, has announced a strategic partnership with Oregon Therapeutics, a distinguished French biotechnology company.…
Kindeva Drug Delivery Expands Manufacturing Capabilities for Eco-Friendly Inhalers at UK Facility
Kindeva Drug Delivery, a prominent figure in the realm of drug-device combination products, has unveiled its plans to bolster its manufacturing capabilities with a second production line for pressurized metered-dose…
JELMYTO® Shows Impressive 86% Recurrence-Free Survival (RFS) at 24 Months Across Varied Patient Profiles: Insights from AUA 2024 Retrospective Analysis
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological…
Exploring New Frontiers in Neuroscience with GE HealthCare’s SIGNA MAGNUS
GE HealthCare (Nasdaq: GEHC) has introduced SIGNA MAGNUS, a head-only magnetic resonance (MR) scanner awaiting FDA 510(k) approval. This cutting-edge technology aims to revolutionize neuroscience research, addressing the limitations of…
Genmab Announces Financial Results for the First Quarter of 2024
The U.S. Food and Drug Administration (U.S. FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) aimed at treating adult patients with relapsed or…
Astellas and Poseida Therapeutics Collaborate to Advance Innovative Allogeneic Cell Therapies for Cancer Treatment
Astellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have announced a strategic collaboration between Astellas’ subsidiary Xyphos Biosciences, Inc. and Poseida. The agreement aims to develop innovative…
4 Ideas for Honoring Teachers During Teacher Appreciation Week, May 6-10
Teacher Appreciation Week arrives annually during the first full week of May, serving as a dedicated time to recognize and celebrate the unwavering commitment of educators worldwide. It presents an…
Amgen Announces Financial Performance for Q1 2024
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite…
Alnylam Pharmaceuticals Releases Q1 2024 Financial Results and Highlights Recent Achievements
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced its financial results for the first quarter ending March 31, 2024, along with notable recent business achievements. Yvonne…
Moderna Unveils Financial Performance for Q1 2024 and Business Developments
Moderna, Inc. (NASDAQ: MRNA) has released its financial results for the first quarter of 2024, along with key updates on its business operations. Stéphane Bancel, the Chief Executive Officer of…